EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study

Šejla Cerić, Timur Cerić, Emir Sokolović, Jasmina Dalač, Dragana Miletić, Inga Marijanović, Layan Mattar, Amina Aljić, Selma Agić-Bilalagić, Amera Šadija, Miran Hadžiahmetović, Semir Bešlija

Biomolecules and Biomedicine · 2025

DOI: 10.17305/bb.2025.12321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, 2025. Verfasst von Šejla Cerić und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Nuclear Medicine, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Thyroid Gland. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for non-small cell lung carcinoma (NSCLC) but are associated with immune-related adverse events (irAEs), including thyroid dysfunction. This study examines the incidence and clinical impact of thyroid dysfunction in NSCLC patients receiving ICIs at the Clinic of Oncology, Clinical Center University of Sarajevo. In this retrospective cohort study of 50 patients with metastatic NSCLC treated with ICIs—either in combination with chemotherapy or as monotherapy for those with programmed death-ligand 1 (PD-L1) expression ≥ 50%—we collected data on demographics, treatment regimens, thyroid function tests, and survival outcomes. Thyroid dysfunction occurred in 24 patients (48%), with 12 (24%) developing hypothyroidism, 4 (8%) developing hyperthyroidism, and 8 (16%) experiencing a transition from hyperthyroidism to hypothyroidism. The incidence of thyroid dysfunction was significantly higher in patients treated with atezolizumab compared to pembrolizumab (P = 0.04), with 87.5% of affected patients receiving atezolizumab. The median time to onset of thyroid dysfunction was 10 cycles (interquartile range [IQR]: 5) for hypothyroidism and six cycles (IQR: 19) for hyperthyroidism. Progression-free survival (PFS) was significantly longer in patients who developed thyroid dysfunction, with the median PFS not reached, compared to a median PFS of 14 months (95% CI: 9.68–18.32) in patients without thyroid dysfunction (P = 0.038). No significant associations were found between thyroid dysfunction and patient age or gender. These findings suggest that thyroid dysfunction is a common irAE in patients with metastatic NSCLC receiving ICIs, particularly atezolizumab, and its development may be associated with improved PFS. Regular monitoring of thyroid function is recommended to promptly identify and manage thyroid abnormalities during ICI therapy, potentially improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsThyroid GlandHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAntibodies, Monoclonal, HumanizedHypothyroidismHyperthyroidismAdultAged, 80 and overTreatment Outcome

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizedpembrolizumabatezolizumab

Autor:innen und Institutionen

  • Clinic for Nuclear Medicine, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Clinic of Oncology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
  • Department for Nuclear Medicine, General Hospital "Prim. dr. Abdulah Nakaš" Sarajevo, Bosnia and Herzegovina.
  • Clinic of Oncology, University Clinical Hospital, Mostar, Bosnia and Herzegovina.
  • Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

Zitieren

APA

Cerić, Š., Cerić, T., Sokolović, E., Dalač, J., Miletić, D., Marijanović, I., Mattar, L., Aljić, A., Agić-Bilalagić, S., Šadija, A., Hadžiahmetović, M., & Bešlija, S. (2025). Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2025.12321

Vancouver

Cerić Š, Cerić T, Sokolović E, Dalač J, Miletić D, Marijanović I, et al. Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study. Biomolecules and Biomedicine. 2025. doi:10.17305/bb.2025.12321

BibTeX
@article{Ceri2025,
  author = {Cerić, Šejla and Cerić, Timur and Sokolović, Emir and Dalač, Jasmina and Miletić, Dragana and Marijanović, Inga and Mattar, Layan and Aljić, Amina and Agić-Bilalagić, Selma and Šadija, Amera and Hadžiahmetović, Miran and Bešlija, Semir},
  title = {Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study},
  journal = {Biomolecules and Biomedicine},
  year = {2025},
  doi = {10.17305/bb.2025.12321}
}
Kostenlos starten →